- Update: Takeda bets $400m in cash on colorectal cancer drug to boost Hutchmed in China Terminal news
- Why HUTCHMED (HCM) stocks are gaining today Benzinga
- Takeda and Hutchmed team up on cancer drug for $1.13 billion FiercePharma
- Takeda to Acquire Exclusive Worldwide License (Excluding China) of Fruquintinib from HUTCHMED, a Highly Selective Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor business thread
- Takeda invests $1 billion more for colorectal cancer drug from Hutchmed BioSpace
- See full coverage on Google News
Update: Takeda bets $400m in cash on colorectal cancer drug to boost China’s Hutchmed – Endpoints News
Bykm636552
Jan 24, 2023